Clinical Trial Update: Down Syndrome Memantine Follow-up Study [Phase 2]

View source ↗

Summary

A Phase 2 follow-up study on memantine in individuals with Down syndrome and intellectual disability has completed, with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Down Syndrome
• Intellectual Disability

Drugs mentioned

• Memantine (memantine)

Snippet

Sponsor: University Hospitals Cleveland Medical Center | Conditions: Down Syndrome, Intellectual Disability | Phase 2 | Status: COMPLETED | Results posted: 2022-04-05